Atara Biotherapeutics Inc. [NASDAQ: ATRA] stock went on a downward path that fall over -8.77% on Tuesday, amounting to a one-week price decrease of less than -4.57%. The company report on July 29, 2020 that Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020.
Live Conference Call and Webcast at 4:30 p.m. EDT.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial results after market close on Wednesday, August 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.
Over the last 12 months, ATRA stock rose by 0.74%. The average equity rating for ATRA stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $927.33 million, with 61.21 million shares outstanding and 43.24 million shares in the current float. Compared to the average trading volume of 1.62M shares, ATRA stock reached a trading volume of 1131063 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Atara Biotherapeutics Inc. [ATRA]:
Evercore ISI have made an estimate for Atara Biotherapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 30, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 15, 2020, representing the official price target for Atara Biotherapeutics Inc. stock. Previously, the target price had yet another raise to $14, while Citigroup analysts kept a Buy rating on ATRA stock. On November 08, 2019, analysts decreased their price target for ATRA shares from 43 to 22.
The Average True Range (ATR) for Atara Biotherapeutics Inc. is set at 0.95 The Price to Book ratio for the last quarter was 2.98, with the Price to Cash per share for the same quarter was set at 2.85.
ATRA Stock Performance Analysis:
Atara Biotherapeutics Inc. [ATRA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.57. With this latest performance, ATRA shares dropped by -20.31% in over the last four-week period, additionally sinking by -11.81% over the last 6 months – not to mention a rise of 0.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATRA stock in for the last two-week period is set at 43.90, with the RSI for the last a single of trading hit 38.46, and the three-weeks RSI is set at 46.58 for Atara Biotherapeutics Inc. [ATRA]. The present Moving Average for the last 50 days of trading for this stock 12.51, while it was recorded at 12.80 for the last single week of trading, and 12.33 for the last 200 days.
Insight into Atara Biotherapeutics Inc. Fundamentals:
Return on Total Capital for ATRA is now -91.49, given the latest momentum, and Return on Invested Capital for the company is -90.33. Return on Equity for this stock declined to -92.43, with Return on Assets sitting at -79.20. When it comes to the capital structure of this company, Atara Biotherapeutics Inc. [ATRA] has a Total Debt to Total Equity ratio set at 5.49. Additionally, ATRA Total Debt to Total Capital is recorded at 5.20, with Total Debt to Total Assets ending up at 4.65. Long-Term Debt to Equity for the company is recorded at 4.95, with the Long-Term Debt to Total Capital now at 4.69.
Reflecting on the efficiency of the workforce at the company, Atara Biotherapeutics Inc. [ATRA] managed to generate an average of -$740,397 per employee.Atara Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.30 and a Current Ratio set at 7.30.
ATRA Stock EPS
With the latest financial reports released by the company, Atara Biotherapeutics Inc. posted -1.6/share EPS, while the average EPS was predicted by analysts to be reported at -1.5/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -6.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATRA.
Atara Biotherapeutics Inc. [ATRA] Insider Position Details
There are presently around $783 million, or 91.40% of ATRA stock, in the hands of institutional investors. The top three institutional holders of ATRA stocks are: BAUPOST GROUP LLC/MA with ownership of 8,308,900, which is approximately 0% of the company’s market cap and around 1.30% of the total institutional ownership; REDMILE GROUP, LLC, holding 5,293,370 shares of the stock with an approximate value of $65.21 million in ATRA stocks shares; and MAVERICK CAPITAL LTD, currently with $64.06 million in ATRA stock with ownership of nearly 4.87% of the company’s market capitalization.
Positions in Atara Biotherapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 72 institutional holders increased their position in Atara Biotherapeutics Inc. [NASDAQ:ATRA] by around 7,926,414 shares. Additionally, 48 investors decreased positions by around 4,568,337 shares, while 17 investors held positions by with 51,064,032 shares. The mentioned changes placed institutional holdings at 63,558,783 shares, according to the latest SEC report filing. ATRA stock had 22 new institutional investments in for a total of 1,750,126 shares, while 27 institutional investors sold positions of 1,013,138 shares during the same period.